Brief: Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease

Palatin Technologies

29/06/2021 12:37

June 29 (Reuters) - Palatin Technologies Inc  PTN.A :
    * PALATIN ANNOUNCES POSITIVE END-OF-PHASE 2 MEETING WITH FDA
ON
PL9643 FOR THE TREATMENT OF DRY EYE DISEASE
    * PALATIN TECHNOLOGIES - CO, FDA REACH AGREEMENT ON PATH TO
NDA
SUBMISSION, INCLUDING TRIAL DESIGN, ENDPOINTS, INTERIM
ASSESSMENT, PATIENT POPULATION
    * PALATIN TECHNOLOGIES INC - ON TRACK TO INITIATE PHASE 3
STUDY
CALENDAR Q4 2021 WITH DATA EXPECTED CALENDAR 2H 2022
    * PALATIN TECHNOLOGIES INC - IF PHASE 3 PROGRAM PROGRESSES
AS
PLANNED, NDA SUBMISSION IS TARGETED FOR SECOND HALF OF CALENDAR
YEAR 2023

Source text for Eikon:  ID:nPn5c8LCHa 
Further company coverage:  PTN.A 

 ((Reuters.Briefs@thomsonreuters.com;))